Rapid clonal development in a relapsed CML 11 years post replete allogeneic bone marrow transplantation.
Long-term survival of chronic myeloid leukaemia (CML) patients transplanted in chronic phase with a replete marrow have been described previously. The same success has not been achieved with patients in more advanced stages of the disease. We describe a CML patient who received an allogeneic bone marrow transplantation in accelerated phase. Cytogenetic and molecular analysis confirmed donor chimaerism, and the absence of the BCR-ABL mRNA. Almost 12 years post-transplant relapse was noted. Cytogenetic analyses showed a complex evolving karyotype. These findings are correlated with the longitudinal molecular analysis utilising real-time and VNTR PCR.
Kearney
P
P
Haematology Department, St Vincent's Hospital Darlinghurst, Darlinghurst, NSW 2010, Sydney, Australia. phil.kearney@activebiotech.com
Suter
M
M
Biggs
J C
JC
D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects*; D017809:Fatal Outcome; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D020350:Graft vs Tumor Effect; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000209:etiology* / Q000235:genetics / Q000628:therapy; D008297:Male; D009364:Neoplasm Recurrence, Local; D012333:RNA, Messenger / Q000032:analysis; D012334:RNA, Neoplasm / Q000032:analysis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors; D018183:Transplantation Chimera / Q000235:genetics*; D014184:Transplantation, Homologous
D012333:RNA, Messenger; D012334:RNA, Neoplasm; D016044:Fusion Proteins, bcr-abl